<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Electron Physician</journal-id><journal-id journal-id-type="iso-abbrev">Electron Physician</journal-id><journal-id journal-id-type="publisher-id">Electronic physician</journal-id><journal-title-group><journal-title>Electronic Physician</journal-title></journal-title-group><issn pub-type="epub">2008-5842</issn><publisher><publisher-name>Electronic physician</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">28894553</article-id><article-id pub-id-type="pmc">5587011</article-id><article-id pub-id-type="doi">10.19082/4899</article-id><article-id pub-id-type="publisher-id">epj-09-4899</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>Effect of alpha-lipoic acid on asymmetric dimethylarginine and disability in multiple sclerosis patients: A randomized clinical trial</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Khalili</surname><given-names>Mohammad</given-names></name><xref ref-type="aff" rid="af1-epj-09-4899">1</xref></contrib><contrib contrib-type="author"><name><surname>Soltani</surname><given-names>Madjid</given-names></name><xref ref-type="aff" rid="af2-epj-09-4899">2</xref><xref ref-type="corresp" rid="c1-epj-09-4899"/></contrib><contrib contrib-type="author"><name><surname>Moghadam</surname><given-names>Shirin Amiri</given-names></name><xref ref-type="aff" rid="af3-epj-09-4899">3</xref></contrib><contrib contrib-type="author"><name><surname>Dehghan</surname><given-names>Parvin</given-names></name><xref ref-type="aff" rid="af4-epj-09-4899">4</xref></contrib><contrib contrib-type="author"><name><surname>Azimi</surname><given-names>Amirreza</given-names></name><xref ref-type="aff" rid="af5-epj-09-4899">5</xref></contrib><contrib contrib-type="author"><name><surname>Abbaszadeh</surname><given-names>Omid</given-names></name><xref ref-type="aff" rid="af6-epj-09-4899">6</xref></contrib></contrib-group><aff id="af1-epj-09-4899">
<label>1</label>Ph.D. of Nutrition, Assistant Professor, Neuroscience Research Center, Tabriz University of Medical Sciences, Tabriz, Iran</aff><aff id="af2-epj-09-4899">
<label>2</label>M.D., Royan Stem Cell Technology, Tehran, Iran</aff><aff id="af3-epj-09-4899">
<label>3</label>M.D., Ph.D. of Nutrition, Assistant Professor, Department of community medicine, Faculty of Medicine, Hormozgan University of Medical Sciences, Bandar Abbas, Iran</aff><aff id="af4-epj-09-4899">
<label>4</label>Ph.D. of Nutrition, Assistant Professor, Department of Food Science and Technology, Faculty of Nutrition and food Sciences, Tabriz University of Medical Sciences, Tabriz, Iran</aff><aff id="af5-epj-09-4899">
<label>5</label>M.D., Neurologist, Assistant Professor, Multiple Sclerosis Research Center, Tehran University of Medical Sciences, Tehran, Iran</aff><aff id="af6-epj-09-4899">
<label>6</label>M.D., Research Development and Coordination Center, faculty of Medicine, Deputy of Research and Technology, Tabriz University of Medical Sciences, Tabriz, Iran</aff><author-notes><corresp id="c1-epj-09-4899">Corresponding author: Dr. Madjid Soltani, Royan Stem Cell Technology, Tehran, Iran. Tel: +98.2127635113, Fax: +98.2189781307, Email: <email>madjsoltani@yahoo.com</email></corresp></author-notes><pub-date pub-type="collection"><month>7</month><year>2017</year></pub-date><pub-date pub-type="epub"><day>25</day><month>7</month><year>2017</year></pub-date><volume>9</volume><issue>7</issue><fpage>4899</fpage><lpage>4905</lpage><history><date date-type="received"><day>21</day><month>7</month><year>2016</year></date><date date-type="accepted"><day>14</day><month>1</month><year>2017</year></date></history><permissions><copyright-statement>&#x000a9; 2017 The Authors</copyright-statement><copyright-year>2017</copyright-year><license><license-p>This is an open access article under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc-nd/3.0/">Creative Commons Attribution-NonCommercial-NoDerivs License</ext-link>, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.</license-p></license></permissions><abstract><sec><title>Background</title><p>Multiple Sclerosis (MS) is an inflammatory and demyelinating disease of the central nervous system. Oxidative stress plays a major role in the onset and progression of MS. Asymmetric dimethylarginine (ADMA) formation is dependent on oxidative stress status.</p></sec><sec><title>Objective</title><p>We examined whether alpha-lipoic acid (ALA) as a potent antioxidant could improve the Expanded Disability Status Scale (EDSS) and decrease plasma level of ADMA in multiple sclerosis patients.</p></sec><sec><title>Methods</title><p>In a randomized, double-blinded clinical trial conducted at Sina Hospital in Tehran, Iran, from September 2009 to July 2011, 24 patients with relapsing-remitting MS were divided into a treatment group receiving ALA (1200mg/day) for 12 weeks and a control group receiving placebo. Then patients&#x02019; EDSS and Plasma levels of ADMA were measured at baseline and 12 weeks later. Statistical analysis was done by SPSS software version 16 using the K-S test, Chi square, Mann&#x02013;Whitney U-test and Wilcoxon test.</p></sec><sec><title>Results</title><p>The plasma levels of ADMA in the intervention group were decreased significantly (p=0.04). Also, no patient had increased EDSS score in the supplement group, where 2 out of 12 patients in the placebo group experienced so. Comparing the serum level of ADMA between the two groups failed to show any significant change in the supplement group compared with the control group.</p></sec><sec><title>Conclusion</title><p>Considering that ADMA is produced by oxidative stress in MS patients and leads to increase of inflammation, ALA may have the potential of beneficial effects in them, in part, by decreasing the plasma level of ADMA and stopping progression.</p></sec><sec><title>Trial registration</title><p>The trial was registered at the Iranian Registry of Clinical Trials (<ext-link ext-link-type="uri" xlink:href="http://www.irct.ir">http://www.irct.ir</ext-link>) with the Irct ID: No. IRCT138812222602N2.</p></sec><sec><title>Funding</title><p>The authors received no financial support for the research, authorship, and/or publication of this article.</p></sec></abstract><kwd-group><kwd>Lipoic acid</kwd><kwd>Multiple sclerosis</kwd><kwd>Inflammation</kwd><kwd>Asymmetric dimethylarginine</kwd></kwd-group></article-meta></front><body><sec><title>1. Introduction</title><p>Multiple sclerosis (MS), an inflammatory and demyelinating disease, affects the central nervous system (CNS) by demyelization and destruction of nerve tissue (<xref rid="b1-epj-09-4899" ref-type="bibr">1</xref>). Therefore, inflammation and degenerative processes are the main cascades in the pathogenesis of MS (<xref rid="b2-epj-09-4899" ref-type="bibr">2</xref>). Nitric Oxide (NO), with different biological functions are produced from L-arginine via NOS activity. Asymmetric dimethylarginine (ADMA) is a major endogenous inhibitor of endothelial NO synthase (eNOS). Recently, a positive association between inflammatory response and ADMA levels had been found in cardiovascular diseases (<xref rid="b3-epj-09-4899" ref-type="bibr">3</xref>). It is proposed that tissue damage in MS is related to the high levels of NO (<xref rid="b4-epj-09-4899" ref-type="bibr">4</xref>, <xref rid="b5-epj-09-4899" ref-type="bibr">5</xref>). In line with this hypothesis, investigations in MS (<xref rid="b6-epj-09-4899" ref-type="bibr">6</xref>, <xref rid="b7-epj-09-4899" ref-type="bibr">7</xref>) and experimental allergic encephalomyelitis (EAE) (<xref rid="b8-epj-09-4899" ref-type="bibr">8</xref>, <xref rid="b9-epj-09-4899" ref-type="bibr">9</xref>) have shown that increase in proinflammatory cytokines TNF-&#x003b1; and INF-g is related with consequent progress in iNOS activity and NO generation. Reactive oxygen species (ROS), direct consequence of neuroinflammation, play a major role in inception and development of MS (<xref rid="b10-epj-09-4899" ref-type="bibr">10</xref>). A new report has indicated that oxidative stress increases the ADMA concentration by enhancing the formation and decreasing the degradation of ADMA (<xref rid="b11-epj-09-4899" ref-type="bibr">11</xref>). Alpha-lipoic acid (ALA), a naturally occurring short chain fatty acid with Sulfhydryl groups, has a potent anti-oxidant activity (<xref rid="b12-epj-09-4899" ref-type="bibr">12</xref>). The beneficial effects of lipoic acid on MS patients have been reported in several investigations (<xref rid="b13-epj-09-4899" ref-type="bibr">13</xref>&#x02013;<xref rid="b15-epj-09-4899" ref-type="bibr">15</xref>). In addition, consumption of ALA led to a drop in plasma ADMA levels in diabetic end-stage renal disease (<xref rid="b16-epj-09-4899" ref-type="bibr">16</xref>). Yet, experimental studies have reported inconsistent roles of NO in the development of neurological immune-pathogen diseases such as multiple sclerosis (MS) (<xref rid="b17-epj-09-4899" ref-type="bibr">17</xref>, <xref rid="b18-epj-09-4899" ref-type="bibr">18</xref>), leaving open the role of NO in this field. In the present study, we assessed whether ALA could improve the Expanded Disability Status Scale (EDSS) and decrease the plasma level of ADMA in multiple sclerosis patients.</p></sec><sec><title>2. Material and Methods</title><sec sec-type="methods|subjects"><title>2.1. Trial design and participants</title><p>This study was a randomized clinical trial that was conducted from September 2009 to July 2011. This study is a pilot study and, to the best of our knowledge, is the first assessing effect of ALA on ADMA in MS patients. The sample size was assumed to be twenty subjects in each group. The MS patients (n=40) with relapsing-remitting course with disease duration more than one year were recruited from a multiple sclerosis clinic at Sina Hospital in Tehran. Diagnosis of MS was done according to McDonalds criteria (<xref rid="b19-epj-09-4899" ref-type="bibr">19</xref>).</p></sec><sec><title>2.2. Selection criteria</title><p>Excluding criteria were ongoing clinical relapse, pregnancy and lactation, the use of corticosteroids, occurrence of relapse attack during the study, and other major medical disorders. Regular consumption of antioxidants or vitamin supplements was also considered as exclusion criteria.</p></sec><sec><title>2.3. Interventions</title><p>The current study was carried out as a randomized double-blinded clinical trial. During the three months of study, from thirty-one patients allocated to interventional groups (ALA group; n=15 and placebo group; n=16) two patients in the lipoic acid group and one in the placebo group were exposed with relapse and excluded from the study. In addition, a patient in the placebo group not attending the complete study, was excluded. Finally, we finished the study with thirteen patients in the ALA and fourteen patients in the placebo group. At endpoint of study, we lost two blood samples in the placebo group and one blood sample in the supplement group. Therefore, results are presented with twelve participants in each group (<xref ref-type="fig" rid="f1-epj-09-4899">Figure 1</xref>). While the placebo and ALA capsules were of the same shape and color, participants in ALA and placebo group took 1200 mg of ALA and placebo as two capsules respectively. The EDSS with scores from 0 and 10 units in half units was used to measure the intensity of MS symptoms and to assess the disease status and treatment. On start point and after three months, all participants underwent EDSS evaluation by the same neurologist. Weight was recorded using a Seca Electronic Weighing Scale (Seca, Hamburg, Germany) to the nearest 100 gr wearing light clothing. Height was measured without shoes, using a non-stretchable tape with accuracy of 0.5 cm. Body mass index (BMI) was determined by dividing the weight (kg) by the square of height (m<sup>2</sup>). After overnight fasting, blood samples (8 ml) were obtained at baseline and at week twelve with subjects seated, in accordance with the standard protocol. Serum ADMA was detected by HPLC methodology (<xref rid="b20-epj-09-4899" ref-type="bibr">20</xref>) on HPLC apparatus (Agilent) with our condition modified fluorometric detection.</p></sec><sec><title>2.4. Outcomes</title><p>The primary outcomes of our analyses were the mean variation of ADMA and EDSS score during study in the two groups. The secondary outcome was percent of patients exposed with rising of EDSS score in each group.</p></sec><sec><title>2.5. Randomization and blinding</title><p>In this clinical trial, using block randomization, participants were assigned randomly to receive either lipoic acid or placebo. We used computer generated randomization sequence through SPSS16 software (SPSS, Inc., Chicago, IL, USA) by one of the researchers who did not have a role in the treatment of the participants. A block size of four was provided for randomized sequence generation. Also, using numbered envelopes which contained the name of the intervention groups, the allocation hiding was done by the researcher who was responsible for the randomization.</p></sec><sec sec-type="methods"><title>2.6. Statistical methods</title><p>The mean and standard deviation were calculated using SPSS 16 software (SPSS, Inc., Chicago, IL, USA). The normality of the variables&#x02019; distribution was examined using the K-S test. Chi square, Mann-Whitney U-test and Wilcoxon tests were used for variables analyzing. The significance level was established at p-value=0.05.</p></sec><sec><title>2.7. Research ethics</title><p>The study was approved by the Ethics Committee of Tehran University of Medical Sciences. The authors confirm that all ongoing and related trials for this intervention are registered. Prior to the study, all the participants were informed by the researcher about the objective and nature of the study, and provided written consent in Persian language. We were committed to keeping all the participants&#x02019; information confidential.</p></sec></sec><sec><title>3. Results</title><p>While, the supplement group had higher mean of EDSS than the control group, comparing baseline values of all parameters failed to show any significant difference between the two groups (<xref ref-type="table" rid="t1-epj-09-4899">Table 1</xref>). The mean plasma level of ADMA in MS patients was 0.37&#x003bc;mol/L, and baseline level of ADMA difference between supplement and control group was not so significant. In the treatment group, however, intake of ALA for 12 weeks significantly reduced the plasma level of ADMA, from a mean of 0.37 to 0.31 &#x003bc;mol/L (p=0.04). In the control participants, the plasma level of ADMA showed slight and non-significant increase during the study. Finally, comparing change of ADMA level between the two groups did not show statistically significant variation in the ALA group compared with the control group (<xref ref-type="table" rid="t2-epj-09-4899">Table 2</xref>). During ALA treatment, EDSS scores in treated patients were slightly and not significant decreasing (at the beginning of the treatment EDSS score was 2.2&#x000b1;1.6, after 12 weeks 1.83&#x000b1;1.5). Instead, EDSS scores did not change significantly in the control group (<xref ref-type="table" rid="t3-epj-09-4899">Table 3</xref>). In addition, we compared disability progression manner to the number of patients with increased EDSS during intervention. Our findings indicated that in the ALA group, no patient had experience of increased EDSS, but in the placebo group 16.5% of patients were exposed with raised EDSS after 12 weeks. The correlation coefficients between base line level of ADMA and EDSS as well as the correlation of their changes during the study were not significant (data were not presented).</p></sec><sec><title>4. Discussion</title><p>This study is the first to assess the effects of ALA on the plasma level of ADMA in multiple sclerosis patients. In this study, we found that supplementation of ALA (1200mg/day) for 12 weeks, leads to a significant reduction in the plasma level of ADMA in MS patients. It is clear that MS is accompanied by inflammatory process as pathogenesis mechanism. This condition is mediated by activated specific and nonspecific immune cells infiltrating CNS tissue. It has been observed that NO generation is due to induction of inducible nitric oxide synthase (iNOS) in macrophages, increasing NO level is a critical component in the onset and development of MS (<xref rid="b7-epj-09-4899" ref-type="bibr">7</xref>, <xref rid="b21-epj-09-4899" ref-type="bibr">21</xref>). This mechanism is a reason for high levels of NO and iNOS in CNS of both MS (<xref rid="b18-epj-09-4899" ref-type="bibr">18</xref>) and EAE (<xref rid="b6-epj-09-4899" ref-type="bibr">6</xref>). For example, the high levels of NO metabolites in the blood and CSF of MS patients have been observed in independent manner to neurological signs (<xref rid="b22-epj-09-4899" ref-type="bibr">22</xref>). It is believed that reactive nitrogen species, with cytotoxic effects on nerve and glial cells, provoke myelin and oligodendrocytes damage (<xref rid="b22-epj-09-4899" ref-type="bibr">22</xref>). ADMA, a natural amino acid, exits in plasma. It is known that the increase of ADMA, results in a suppression of the NO production by inhibition of NOS activity. Stojanovic and collogues reported that plasma concentration of ADMA in healthy people and MS patients is less than 1 &#x003bc;mol/l (<xref rid="b23-epj-09-4899" ref-type="bibr">23</xref>). Similarly, in our study the ADMA level in MS patients is found in less than 1 &#x003bc;mol/l. In another investigation, in patients suffering from multiple sclerosis, CSF ADMA levels were elevated (<xref rid="b24-epj-09-4899" ref-type="bibr">24</xref>). Positive correlation of ADMA levels with intensity of clinical severity was reported in inflammatory bowel disease (<xref rid="b25-epj-09-4899" ref-type="bibr">25</xref>). Furthermore, during interferon-&#x003b2;1b treatment in multiple sclerosis patients, ADMA levels were significantly increased compared to the baseline levels which were accompanied by decrease in EDSS level in treated patients (<xref rid="b23-epj-09-4899" ref-type="bibr">23</xref>). Regarding our results, treatment with ALA led to a decrease in ADMA levels as well as a halt in disability progression. These facts are in correlation with literature data from an experimental model of MS, reporting that ALA slows down the ICAM-1 and VCAM-1 and suppresses the infiltration of T cells through the blood brain barrier (<xref rid="b26-epj-09-4899" ref-type="bibr">26</xref>&#x02013;<xref rid="b28-epj-09-4899" ref-type="bibr">28</xref>). Mentioned evidence found that ROS are important factors mediating injury in EAE and that generation of ROS can be decreased by ALA. Also, ALA decreased the migration of monocytes through the blood brain barrier, which was correlated with the clinical improvement in EAE. However, there is no clear evidence evaluating direct correlation of ADMA level with clinical severity of MS. This study showed that ALA decreases circulating ADMA concentrations in patients with multiple sclerosis. Similarly, Chang and colleagues found that consumption of LA (600mg/day) decreased ADMA levels in a treated group of diabetic end-stage renal disease (<xref rid="b16-epj-09-4899" ref-type="bibr">16</xref>). ALA, as a potent antioxidant and anti-inflammation supplement, has been used in treatment of MS and suppressed proinflammatory cytokines levels such as TNF-&#x003b1; and INF-g in EAE models and MS patients (<xref rid="b28-epj-09-4899" ref-type="bibr">28</xref>, <xref rid="b29-epj-09-4899" ref-type="bibr">29</xref>). In agreement with our results, researchers indicate that ALA decreases ADMA level in diabetes mellitus (<xref rid="b30-epj-09-4899" ref-type="bibr">30</xref>). ADMA is excreted via the kidneys and mainly metabolized by the enzyme dimethylarginine dimethylamino hydrolase (DDAH) (<xref rid="b31-epj-09-4899" ref-type="bibr">31</xref>), which is sensitive to oxidative stress (<xref rid="b32-epj-09-4899" ref-type="bibr">32</xref>). It is proposed that ALA via antioxidant properties could influence DDAH. Hence, accumulation of ADMA in nerve cells due to produced proinflammatory cytokines, such as TNF-&#x003b1; (<xref rid="b33-epj-09-4899" ref-type="bibr">33</xref>) as well as suppressing effect of ALA on TNF-&#x003b1; level in MS patients (<xref rid="b15-epj-09-4899" ref-type="bibr">15</xref>, <xref rid="b29-epj-09-4899" ref-type="bibr">29</xref>) may be explanations for our results.</p></sec><sec><title>5. Limitation</title><p>The limitation of this study is that it does not show the clear mechanism by which ALA decreases the plasma level of ADMA. In addition, this study did not consider the potential for NO generation by the ADMA or give information on the activity of the DDAH enzyme that degrades ADMA.</p></sec><sec><title>6. Conclusions</title><p>Regarding our findings, ALA supplementation decreased ADMA levels and led to observe no patient with increased disability score during the study. But decrease of disability score in the ALA group was not significant. Considering that ADMA is produced by inflammation, however, ALA could have the potential to have beneficial effects on MS patients. We think that further studies with large samples and extended duration are needed to prove the effectiveness of ALA on the progression of multiple sclerosis.</p></sec></body><back><ack><title>Acknowledgments</title><p>This paper was extracted from a nutrition PhD thesis at Tehran University of Medical Sciences in Tehran, Iran. The authors appreciate the assistance and cooperation provided by the staff members in the Sina and Emam Khomeyni Hospitals. Also, we appreciate the assistance provided by Mr. Meysam Sanoobar (MSc in Nutrition) and Dr. Ghazaleh Skandari (MD). Authors thank all patients who participated in study.</p></ack><fn-group><fn id="fn1-epj-09-4899"><p>iThenticate screening: October 09, 2016, English editing: May 17, 2017, Quality control: June 15, 2017</p></fn><fn id="fn2-epj-09-4899" fn-type="COI-statement"><p><bold>Conflict of Interest:</bold></p><p>There is no conflict of interest to be declared.</p></fn><fn id="fn3-epj-09-4899"><p><bold>Authors&#x02019; contributions:</bold></p><p>All authors contributed to this project and article equally. All authors read and approved the final manuscript.</p></fn></fn-group><ref-list><title>References</title><ref id="b1-epj-09-4899"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Babaloo</surname><given-names>Z</given-names></name><name><surname>Babaie</surname><given-names>F</given-names></name><name><surname>Farhoodi</surname><given-names>M</given-names></name><name><surname>Aliparasti</surname><given-names>MR</given-names></name><name><surname>Baradaran</surname><given-names>B</given-names></name><name><surname>Almasi</surname><given-names>S</given-names></name><etal/></person-group><article-title>Interleukin-17A and Interleukin-17F mRNA Expressions in Peripheral Blood Mononuclear Cells of Patients with Multiple Sclerosis</article-title><source>Iran J Immunol</source><year>2010</year><volume>7</volume><issue>4</issue><fpage>202</fpage><lpage>9</lpage><comment>IJIv7i4A1</comment><pub-id pub-id-type="pmid">21189442</pub-id></element-citation></ref><ref id="b2-epj-09-4899"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lassmann</surname><given-names>H</given-names></name><name><surname>Br&#x000fc;ck</surname><given-names>W</given-names></name><name><surname>Lucchinetti</surname><given-names>C</given-names></name></person-group><article-title>Heterogeneity of multiple sclerosis pathogenesis: implications for diagnosis and therapy</article-title><source>Trends Mol Med</source><year>2001</year><volume>7</volume><issue>3</issue><fpage>115</fpage><lpage>21</lpage><pub-id pub-id-type="doi">10.1016/S1471-4914(00)01909-2</pub-id><pub-id pub-id-type="pmid">11286782</pub-id></element-citation></ref><ref id="b3-epj-09-4899"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sandoo</surname><given-names>A</given-names></name><name><surname>Dimitroulas</surname><given-names>T</given-names></name><name><surname>Hodson</surname><given-names>J</given-names></name><name><surname>Smith</surname><given-names>JP</given-names></name><name><surname>Douglas</surname><given-names>KM</given-names></name><name><surname>Kitas</surname><given-names>GD</given-names></name></person-group><article-title>Cumulative inflammation associates with asymmetric dimethylarginine in rheumatoid arthritis: a 6 year follow-up study</article-title><source>Rheumatology (Oxford)</source><year>2015</year><volume>54</volume><issue>7</issue><fpage>1145</fpage><lpage>52</lpage><pub-id pub-id-type="doi">10.1093/rheumatology/keu349</pub-id><pub-id pub-id-type="pmid">25187642</pub-id></element-citation></ref><ref id="b4-epj-09-4899"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ghasemi</surname><given-names>M</given-names></name><name><surname>Fatemi</surname><given-names>A</given-names></name></person-group><article-title>Pathologic role of glial nitric oxide in adult and pediatric neuroinflammatory diseases</article-title><source>Neurosci Biobehav Rev</source><year>2014</year><volume>45</volume><fpage>168</fpage><lpage>82</lpage><pub-id pub-id-type="doi">10.1016/j.neubiorev.2014.06.002</pub-id><pub-id pub-id-type="pmid">24933692</pub-id></element-citation></ref><ref id="b5-epj-09-4899"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Smith</surname><given-names>KJ</given-names></name><name><surname>Kapoor</surname><given-names>R</given-names></name><name><surname>Felts</surname><given-names>PA</given-names></name></person-group><article-title>Demyelination: the role of reactive oxygen and nitrogen species</article-title><source>Brain Pathol</source><year>1999</year><volume>9</volume><issue>1</issue><fpage>69</fpage><lpage>92</lpage><pub-id pub-id-type="doi">10.1111/j.1750-3639.1999.tb00212.x</pub-id><pub-id pub-id-type="pmid">9989453</pub-id></element-citation></ref><ref id="b6-epj-09-4899"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>B&#x000f6;</surname><given-names>L</given-names></name><name><surname>Dawson</surname><given-names>TM</given-names></name><name><surname>Wesselingh</surname><given-names>S</given-names></name><name><surname>M&#x000f6;urk</surname><given-names>S</given-names></name><name><surname>Choi</surname><given-names>S</given-names></name><name><surname>Kong</surname><given-names>PA</given-names></name><etal/></person-group><article-title>Induction of nitric oxide synthase in demyelinating regions of multiple sclerosis brains</article-title><source>Ann Neurol</source><year>1994</year><volume>36</volume><issue>5</issue><fpage>778</fpage><lpage>86</lpage><pub-id pub-id-type="doi">10.1002/ana.410360515</pub-id><pub-id pub-id-type="pmid">7526776</pub-id></element-citation></ref><ref id="b7-epj-09-4899"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bagasra</surname><given-names>O</given-names></name><name><surname>Michaels</surname><given-names>FH</given-names></name><name><surname>Zheng</surname><given-names>YM</given-names></name><name><surname>Bobroski</surname><given-names>LE</given-names></name><name><surname>Spitsin</surname><given-names>SV</given-names></name><name><surname>Fu</surname><given-names>ZF</given-names></name><etal/></person-group><article-title>Activation of the inducible form of nitric oxide synthase in the brains of patients with multiple sclerosis</article-title><source>Proc Natl Acad Sci U S A</source><year>1995</year><volume>92</volume><issue>26</issue><fpage>12041</fpage><lpage>5</lpage><pub-id pub-id-type="doi">10.1073/pnas.92.26.12041</pub-id><!--<pub-id pub-id-type="pmcid">PMC40292</pub-id>--><pub-id pub-id-type="pmid">8618840</pub-id></element-citation></ref><ref id="b8-epj-09-4899"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Endoh</surname><given-names>M</given-names></name><name><surname>Maiese</surname><given-names>K</given-names></name><name><surname>Wagner</surname><given-names>J</given-names></name></person-group><article-title>Expression of the inducible form of nitric oxide synthase by reactive astrocytes after transient global ischemia</article-title><source>Brain Res</source><year>1994</year><volume>651</volume><issue>1&#x02013;2</issue><fpage>92</fpage><lpage>100</lpage><pub-id pub-id-type="doi">10.1016/0006-8993(94)90683-1</pub-id><pub-id pub-id-type="pmid">7522935</pub-id></element-citation></ref><ref id="b9-epj-09-4899"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lin</surname><given-names>RF</given-names></name><name><surname>Lin</surname><given-names>TS</given-names></name><name><surname>Tilton</surname><given-names>RG</given-names></name><name><surname>Cross</surname><given-names>AH</given-names></name></person-group><article-title>Nitric oxide localized to spinal cords of mice with experimental allergic encephalomyelitis: an electron paramagnetic resonance study</article-title><source>J Exp Med</source><year>1993</year><volume>178</volume><issue>2</issue><fpage>643</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1084/jem.178.2.643</pub-id><!--<pub-id pub-id-type="pmcid">PMC2191106</pub-id>--><pub-id pub-id-type="pmid">8393479</pub-id></element-citation></ref><ref id="b10-epj-09-4899"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gilgun-Sherki</surname><given-names>Y</given-names></name><name><surname>Melamed</surname><given-names>E</given-names></name><name><surname>Offen</surname><given-names>D</given-names></name></person-group><article-title>The role of oxidative stress in the pathogenesis of multiple sclerosis: the need for effective antioxidant therapy</article-title><source>J Neurol</source><year>2004</year><volume>251</volume><issue>3</issue><fpage>261</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1007/s00415-004-0348-9</pub-id><pub-id pub-id-type="pmid">15015004</pub-id></element-citation></ref><ref id="b11-epj-09-4899"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Luo</surname><given-names>Y</given-names></name><name><surname>Yue</surname><given-names>W</given-names></name><name><surname>Quan</surname><given-names>X</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Zhao</surname><given-names>B</given-names></name><name><surname>Lu</surname><given-names>Z</given-names></name></person-group><article-title>Asymmetric dimethylarginine exacerbates A&#x003b2;-induced toxicity and oxidative stress in human cell and Caenorhabditis elegans models of Alzheimer disease</article-title><source>Free Radic Biol Med</source><year>2015</year><volume>79</volume><fpage>117</fpage><lpage>26</lpage><pub-id pub-id-type="doi">10.1016/j.freeradbiomed.2014.12.002</pub-id><pub-id pub-id-type="pmid">25499850</pub-id></element-citation></ref><ref id="b12-epj-09-4899"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moini</surname><given-names>H</given-names></name><name><surname>Packer</surname><given-names>L</given-names></name><name><surname>Saris</surname><given-names>NE</given-names></name></person-group><article-title>Antioxidant and prooxidant activities of &#x003b1;-lipoic acid and dihydrolipoic acid</article-title><source>Toxicol Appl Pharmacol</source><year>2002</year><volume>182</volume><issue>1</issue><fpage>84</fpage><lpage>90</lpage><pub-id pub-id-type="doi">10.1006/taap.2002.9437</pub-id><pub-id pub-id-type="pmid">12127266</pub-id></element-citation></ref><ref id="b13-epj-09-4899"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Khalili</surname><given-names>M</given-names></name><name><surname>Eghtesadi</surname><given-names>S</given-names></name><name><surname>Mirshafiey</surname><given-names>A</given-names></name><name><surname>Eskandari</surname><given-names>G</given-names></name><name><surname>Sanoobar</surname><given-names>M</given-names></name><name><surname>Sahraian</surname><given-names>MA</given-names></name><etal/></person-group><article-title>Effect of lipoic acid consumption on oxidative stress among multiple sclerosis patients: A randomized controlled clinical trial</article-title><source>Nutr Neurosci</source><year>2014</year><volume>17</volume><issue>1</issue><fpage>16</fpage><lpage>20</lpage><pub-id pub-id-type="doi">10.1179/1476830513Y.0000000060</pub-id><pub-id pub-id-type="pmid">23485514</pub-id></element-citation></ref><ref id="b14-epj-09-4899"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yadav</surname><given-names>V</given-names></name><name><surname>Marracci</surname><given-names>G</given-names></name><name><surname>Lovera</surname><given-names>J</given-names></name><name><surname>Woodward</surname><given-names>W</given-names></name><name><surname>Bogardus</surname><given-names>K</given-names></name><name><surname>Marquardt</surname><given-names>W</given-names></name><etal/></person-group><article-title>Lipoic acid in multiple sclerosis: a pilot study</article-title><source>Mult Scler</source><year>2005</year><volume>11</volume><issue>2</issue><fpage>159</fpage><lpage>65</lpage><pub-id pub-id-type="doi">10.1191/1352458505ms1143oa</pub-id><pub-id pub-id-type="pmid">15794388</pub-id></element-citation></ref><ref id="b15-epj-09-4899"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Salinthone</surname><given-names>S</given-names></name><name><surname>Yadav</surname><given-names>V</given-names></name><name><surname>Bourdette</surname><given-names>DN</given-names></name><name><surname>Carr</surname><given-names>DW</given-names></name></person-group><article-title>Lipoic acid: a novel therapeutic approach for multiple sclerosis and other chronic inflammatory diseases of the CNS</article-title><source>Endocr Metab Immune Disord Drug Targets</source><year>2008</year><volume>8</volume><issue>2</issue><fpage>132</fpage><lpage>42</lpage><pub-id pub-id-type="doi">10.2174/187153008784534303</pub-id><pub-id pub-id-type="pmid">18537699</pub-id></element-citation></ref><ref id="b16-epj-09-4899"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chang</surname><given-names>JW</given-names></name><name><surname>Lee</surname><given-names>EK</given-names></name><name><surname>Kim</surname><given-names>TH</given-names></name><name><surname>Min</surname><given-names>WK</given-names></name><name><surname>Chun</surname><given-names>S</given-names></name><name><surname>Lee</surname><given-names>KU</given-names></name><etal/></person-group><article-title>Effects of &#x003b1;-lipoic acid on the plasma levels of asymmetric dimethylarginine in diabetic end-stage renal disease patients on hemodialysis: a pilot study</article-title><source>Am J Nephrol</source><year>2007</year><volume>27</volume><issue>1</issue><fpage>70</fpage><lpage>4</lpage><pub-id pub-id-type="doi">10.1159/000099035</pub-id><pub-id pub-id-type="pmid">17259696</pub-id></element-citation></ref><ref id="b17-epj-09-4899"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mitrovic</surname><given-names>B</given-names></name><name><surname>Ignarro</surname><given-names>LJ</given-names></name><name><surname>Vinters</surname><given-names>HV</given-names></name><name><surname>Akers</surname><given-names>MA</given-names></name><name><surname>Schmid</surname><given-names>I</given-names></name><name><surname>Uittenbogaart</surname><given-names>C</given-names></name><etal/></person-group><article-title>Nitric oxide induces necrotic but not apoptotic cell death in oligodendrocytes</article-title><source>Neuroscience</source><year>1995</year><volume>65</volume><issue>2</issue><fpage>531</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1016/0306-4522(94)00491-M</pub-id><pub-id pub-id-type="pmid">7777166</pub-id></element-citation></ref><ref id="b18-epj-09-4899"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Smith</surname><given-names>KJ</given-names></name><name><surname>Lassmann</surname><given-names>H</given-names></name></person-group><article-title>The role of nitric oxide in multiple sclerosis</article-title><source>Lancet Neurol</source><year>2002</year><volume>1</volume><issue>4</issue><fpage>232</fpage><lpage>41</lpage><pub-id pub-id-type="doi">10.1016/S1474-4422(02)00102-3</pub-id><pub-id pub-id-type="pmid">12849456</pub-id></element-citation></ref><ref id="b19-epj-09-4899"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Polman</surname><given-names>CH</given-names></name><name><surname>Reingold</surname><given-names>SC</given-names></name><name><surname>Banwell</surname><given-names>B</given-names></name><name><surname>Clanet</surname><given-names>M</given-names></name><name><surname>Cohen</surname><given-names>JA</given-names></name><name><surname>Filippi</surname><given-names>M</given-names></name><etal/></person-group><article-title>Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria</article-title><source>Ann Neurol</source><year>2011</year><volume>69</volume><issue>2</issue><fpage>292</fpage><lpage>302</lpage><pub-id pub-id-type="doi">10.1002/ana.22366</pub-id><!--<pub-id pub-id-type="pmcid">PMC3084507</pub-id>--><pub-id pub-id-type="pmid">21387374</pub-id></element-citation></ref><ref id="b20-epj-09-4899"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pi</surname><given-names>J</given-names></name><name><surname>Kumagai</surname><given-names>Y</given-names></name><name><surname>Sun</surname><given-names>G</given-names></name><name><surname>Shimojo</surname><given-names>N</given-names></name></person-group><article-title>Improved method for simultaneous determination of L-arginine and its mono-and dimethylated metabolites in biological samples by high-performance liquid chromatography</article-title><source>J Chromatogr B Biomed Sci Appl</source><year>2000</year><volume>742</volume><issue>1</issue><fpage>199</fpage><lpage>203</lpage><pub-id pub-id-type="doi">10.1016/S0378-4347(00)00145-6</pub-id><pub-id pub-id-type="pmid">10892599</pub-id></element-citation></ref><ref id="b21-epj-09-4899"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Koprowski</surname><given-names>H</given-names></name><name><surname>Zheng</surname><given-names>YM</given-names></name><name><surname>Heber-Katz</surname><given-names>E</given-names></name><name><surname>Fraser</surname><given-names>N</given-names></name><name><surname>Rorke</surname><given-names>L</given-names></name><name><surname>Fu</surname><given-names>ZF</given-names></name><etal/></person-group><article-title>In vivo expression of inducible nitric oxide synthase in experimentally induced neurologic diseases</article-title><source>Proc Natl Acad Sci U S A</source><year>1993</year><volume>90</volume><issue>7</issue><fpage>3024</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.1073/pnas.90.7.3024</pub-id><!--<pub-id pub-id-type="pmcid">PMC46229</pub-id>--><pub-id pub-id-type="pmid">7681993</pub-id></element-citation></ref><ref id="b22-epj-09-4899"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Johnson</surname><given-names>AW</given-names></name><name><surname>Land</surname><given-names>JM</given-names></name><name><surname>Thompson</surname><given-names>EJ</given-names></name><name><surname>Bola&#x000f1;os</surname><given-names>JP</given-names></name><name><surname>Clark</surname><given-names>JB</given-names></name><name><surname>Heales</surname><given-names>SJ</given-names></name></person-group><article-title>Evidence for increased nitric oxide production in multiple sclerosis</article-title><source>J Neurol Neurosurg Psychiatry</source><year>1995</year><volume>58</volume><issue>1</issue><fpage>107</fpage><pub-id pub-id-type="doi">10.1136/jnnp.58.1.107</pub-id><!--<pub-id pub-id-type="pmcid">PMC1073282</pub-id>--><pub-id pub-id-type="pmid">7823050</pub-id></element-citation></ref><ref id="b23-epj-09-4899"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stojanovic</surname><given-names>I</given-names></name><name><surname>Vojinovic</surname><given-names>S</given-names></name><name><surname>Ljubisavljevic</surname><given-names>S</given-names></name><name><surname>Pavlovic</surname><given-names>R</given-names></name><name><surname>Basic</surname><given-names>J</given-names></name><name><surname>Pavlovic</surname><given-names>D</given-names></name><etal/></person-group><article-title>INF-&#x003b2;1b therapy modulates l-arginine and nitric oxide metabolism in patients with relapse remittent multiple sclerosis</article-title><source>J Neurol Sci</source><year>2012</year><volume>323</volume><issue>1&#x02013;2</issue><fpage>187</fpage><lpage>92</lpage><pub-id pub-id-type="doi">10.1016/j.jns.2012.09.014</pub-id><pub-id pub-id-type="pmid">23026532</pub-id></element-citation></ref><ref id="b24-epj-09-4899"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Conte</surname><given-names>C</given-names></name><name><surname>Floridi</surname><given-names>E</given-names></name><name><surname>Galli</surname><given-names>F</given-names></name><name><surname>Aisa</surname><given-names>C</given-names></name><name><surname>Floridi</surname><given-names>A</given-names></name></person-group><article-title>A new method for the liquid chromatography analysis of methylated arginines in biological fluids and tissues by o-phthaldialdehyde postcolumn derivatization</article-title><source>Anal Biochem</source><year>2005</year><volume>338</volume><issue>2</issue><fpage>347</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1016/j.ab.2004.11.018</pub-id><pub-id pub-id-type="pmid">15745758</pub-id></element-citation></ref><ref id="b25-epj-09-4899"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Owczarek</surname><given-names>D</given-names></name><name><surname>Cibor</surname><given-names>D</given-names></name><name><surname>Mach</surname><given-names>T</given-names></name></person-group><article-title>Asymmetric dimethylarginine (ADMA), symmetric dimethylarginine (SDMA), arginine, and 8-iso-prostaglandin F2&#x003b1; (8-iso-PGF2&#x003b1;) level in patients with inflammatory bowel diseases</article-title><source>Inflamm Bowel Dis</source><year>2010</year><volume>16</volume><issue>1</issue><fpage>52</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.1002/ibd.20994</pub-id><pub-id pub-id-type="pmid">19575355</pub-id></element-citation></ref><ref id="b26-epj-09-4899"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schreibelt</surname><given-names>G</given-names></name><name><surname>Musters</surname><given-names>RJ</given-names></name><name><surname>Reijerkerk</surname><given-names>A</given-names></name><name><surname>de Groot</surname><given-names>LR</given-names></name><name><surname>van der Pol</surname><given-names>SM</given-names></name><name><surname>Hendrikx</surname><given-names>EM</given-names></name><etal/></person-group><article-title>Lipoic acid affects cellular migration into the central nervous system and stabilizes blood-brain barrier integrity</article-title><source>J Immunol</source><year>2006</year><volume>177</volume><issue>4</issue><fpage>2630</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.177.4.2630</pub-id><pub-id pub-id-type="pmid">16888025</pub-id></element-citation></ref><ref id="b27-epj-09-4899"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marracci</surname><given-names>GH</given-names></name><name><surname>McKeon</surname><given-names>GP</given-names></name><name><surname>Marquardt</surname><given-names>WE</given-names></name><name><surname>Winter</surname><given-names>RW</given-names></name><name><surname>Riscoe</surname><given-names>MK</given-names></name><name><surname>Bourdette</surname><given-names>DN</given-names></name></person-group><article-title>Alpha lipoic acid inhibits human T-cell migration: implications for multiple sclerosis</article-title><source>J Neurosci Res</source><year>2004</year><volume>78</volume><issue>3</issue><fpage>362</fpage><lpage>70</lpage><pub-id pub-id-type="doi">10.1002/jnr.20255</pub-id><pub-id pub-id-type="pmid">15389837</pub-id></element-citation></ref><ref id="b28-epj-09-4899"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chaudhary</surname><given-names>P</given-names></name><name><surname>Marracci</surname><given-names>GH</given-names></name><name><surname>Bourdette</surname><given-names>DN</given-names></name></person-group><article-title>Lipoic acid inhibits expression of ICAM-1 and VCAM-1 by CNS endothelial cells and T cell migration into the spinal cord in experimental autoimmune encephalomyelitis</article-title><source>J Neuroimmunol</source><year>2006</year><volume>175</volume><issue>1&#x02013;2</issue><fpage>87</fpage><lpage>96</lpage><pub-id pub-id-type="doi">10.1016/j.jneuroim.2006.03.007</pub-id><pub-id pub-id-type="pmid">16644024</pub-id></element-citation></ref><ref id="b29-epj-09-4899"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Khalili</surname><given-names>M</given-names></name><name><surname>Azimi</surname><given-names>A</given-names></name><name><surname>Izadi</surname><given-names>V</given-names></name><name><surname>Eghtesadi</surname><given-names>S</given-names></name><name><surname>Mirshafiey</surname><given-names>A</given-names></name><name><surname>Sahraian</surname><given-names>MA</given-names></name><etal/></person-group><article-title>Does Lipoic Acid Consumption Affect the Cytokine Profile in Multiple Sclerosis Patients: A Double-Blind, Placebo-Controlled, Randomized Clinical Trial</article-title><source>Neuroimmunomodulation</source><year>2014</year><volume>21</volume><issue>6</issue><fpage>291</fpage><lpage>6</lpage><pub-id pub-id-type="doi">10.1159/000356145</pub-id><pub-id pub-id-type="pmid">24821457</pub-id></element-citation></ref><ref id="b30-epj-09-4899"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mittermayer</surname><given-names>F</given-names></name><name><surname>Pleiner</surname><given-names>J</given-names></name><name><surname>Francesconi</surname><given-names>M</given-names></name><name><surname>Wolzt</surname><given-names>M</given-names></name></person-group><article-title>Treatment with &#x003b1;-lipoic acid reduces asymmetric dimethylarginine in patients with type 2 diabetes mellitus</article-title><source>Transl Res</source><year>2010</year><volume>155</volume><issue>1</issue><fpage>6</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1016/j.trsl.2009.08.004</pub-id><pub-id pub-id-type="pmid">20004356</pub-id></element-citation></ref><ref id="b31-epj-09-4899"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vallance</surname><given-names>P</given-names></name><name><surname>Leiper</surname><given-names>J</given-names></name></person-group><article-title>Cardiovascular biology of the asymmetric dimethylarginine: dimethylarginine dimethylaminohydrolase pathway</article-title><source>Arterioscler Thromb Vasc Biol</source><year>2004</year><volume>24</volume><issue>6</issue><fpage>1023</fpage><lpage>30</lpage><pub-id pub-id-type="doi">10.1161/01.ATV.0000128897.54893.26</pub-id><pub-id pub-id-type="pmid">15105281</pub-id></element-citation></ref><ref id="b32-epj-09-4899"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lin</surname><given-names>KY</given-names></name><name><surname>Ito</surname><given-names>A</given-names></name><name><surname>Asagami</surname><given-names>T</given-names></name><name><surname>Tsao</surname><given-names>PS</given-names></name><name><surname>Adimoolam</surname><given-names>S</given-names></name><name><surname>Kimoto</surname><given-names>M</given-names></name><etal/></person-group><article-title>Impaired nitric oxide synthase pathway in diabetes mellitus role of asymmetric dimethylarginine and dimethylarginine dimethylaminohydrolase</article-title><source>Circulation</source><year>2002</year><volume>106</volume><issue>8</issue><fpage>987</fpage><lpage>92</lpage><pub-id pub-id-type="doi">10.1161/01.CIR.0000027109.14149.67</pub-id><pub-id pub-id-type="pmid">12186805</pub-id></element-citation></ref><ref id="b33-epj-09-4899"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leiper</surname><given-names>J</given-names></name><name><surname>Vallance</surname><given-names>P</given-names></name></person-group><article-title>Biological significance of endogenous methylarginines that inhibit nitric oxide synthases</article-title><source>Cardiovasc Res</source><year>1999</year><volume>43</volume><issue>3</issue><fpage>542</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1016/S0008-6363(99)00162-5</pub-id><pub-id pub-id-type="pmid">10690326</pub-id></element-citation></ref></ref-list></back><floats-group><fig id="f1-epj-09-4899" position="float"><label>Figure 1</label><caption><p>Subjects&#x02019; disposition</p></caption><graphic xlink:href="EPJ-09-4899-g001"/></fig><table-wrap id="t1-epj-09-4899" position="float"><label>Table 1</label><caption><p>Demographic characteristics at baseline (Mean&#x000b1;SD).</p></caption><table frame="box" rules="all"><thead><tr><th valign="top" align="left" rowspan="1" colspan="1">Variable</th><th valign="top" align="left" rowspan="1" colspan="1">Supplement group (n=12)</th><th valign="top" align="left" rowspan="1" colspan="1">Placebo group (n=12)</th><th valign="top" align="left" rowspan="1" colspan="1">p-value</th></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1">Age (year)</td><td valign="top" align="left" rowspan="1" colspan="1">32.3&#x000b1;6.2</td><td valign="top" align="left" rowspan="1" colspan="1">32.2&#x000b1;10.5</td><td valign="top" align="left" rowspan="1" colspan="1">0.78</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Sex (F/M) n</td><td valign="top" align="left" rowspan="1" colspan="1">7/5</td><td valign="top" align="left" rowspan="1" colspan="1">11/1</td><td valign="top" align="left" rowspan="1" colspan="1">0.07</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Duration of disease (month)</td><td valign="top" align="left" rowspan="1" colspan="1">53.83&#x000b1;53.82</td><td valign="top" align="left" rowspan="1" colspan="1">69.00&#x000b1;64.34</td><td valign="top" align="left" rowspan="1" colspan="1">0.67</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">EDSS</td><td valign="top" align="left" rowspan="1" colspan="1">2.20&#x000b1;1.60</td><td valign="top" align="left" rowspan="1" colspan="1">1.54&#x000b1;1.32</td><td valign="top" align="left" rowspan="1" colspan="1">0.31</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">BMI(kg/m<sup>2</sup>)</td><td valign="top" align="left" rowspan="1" colspan="1">24.1&#x000b1;2.9</td><td valign="top" align="left" rowspan="1" colspan="1">23.9&#x000b1;2.3</td><td valign="top" align="left" rowspan="1" colspan="1">0.73</td></tr></tbody></table></table-wrap><table-wrap id="t2-epj-09-4899" position="float"><label>Table 2</label><caption><p>Baseline and end point level of ADMA and change after placebo or supplement application in patients (Mean&#x000b1;SD).</p></caption><table frame="box" rules="all"><thead><tr><th valign="top" align="left" rowspan="1" colspan="1">Variable</th><th valign="top" align="left" rowspan="1" colspan="1">Supplement group (n=12)</th><th valign="top" align="left" rowspan="1" colspan="1">Control group (n=12)</th><th valign="top" align="left" rowspan="1" colspan="1">p-value</th></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1">Base line ADMA(&#x003bc;mol/L)</td><td valign="top" align="left" rowspan="1" colspan="1">0.37&#x000b1;0.08</td><td valign="top" align="left" rowspan="1" colspan="1">0.35&#x000b1;0.10</td><td valign="top" align="left" rowspan="1" colspan="1">0.41</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">End point ADMA (&#x003bc;mol/L)</td><td valign="top" align="left" rowspan="1" colspan="1">0.31&#x000b1;0.06</td><td valign="top" align="left" rowspan="1" colspan="1">0.37&#x000b1;0.14</td><td valign="top" align="left" rowspan="1" colspan="1">0.19</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Difference (&#x003bc;mol/L)</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02212;0.06&#x000b1;0.09</td><td valign="top" align="left" rowspan="1" colspan="1">0.02&#x000b1;0.19</td><td valign="top" align="left" rowspan="1" colspan="1">0.29</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">p-value</td><td valign="top" align="left" rowspan="1" colspan="1">0.04</td><td valign="top" align="left" rowspan="1" colspan="1">0.96</td><td valign="top" align="left" rowspan="1" colspan="1"/></tr></tbody></table></table-wrap><table-wrap id="t3-epj-09-4899" position="float"><label>Table 3</label><caption><p>Baseline and end point level of EDSS and change after placebo or supplement application in patients (Mean&#x000b1;SD).</p></caption><table frame="box" rules="all"><thead><tr><th valign="top" align="left" rowspan="1" colspan="1">Variable</th><th valign="top" align="left" rowspan="1" colspan="1">Supplement group (n=12)</th><th valign="top" align="left" rowspan="1" colspan="1">Control group (n=12)</th><th valign="top" align="left" rowspan="1" colspan="1">p-value</th></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1">Base line EDSS</td><td valign="top" align="left" rowspan="1" colspan="1">2.20&#x000b1;1.60</td><td valign="top" align="left" rowspan="1" colspan="1">1.54&#x000b1;1.32</td><td valign="top" align="left" rowspan="1" colspan="1">0.31</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">End point EDSS</td><td valign="top" align="left" rowspan="1" colspan="1">1.83&#x000b1;1.51</td><td valign="top" align="left" rowspan="1" colspan="1">1.54&#x000b1;1.48</td><td valign="top" align="left" rowspan="1" colspan="1">0.67</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Difference</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02212;0.37&#x000b1;0.77</td><td valign="top" align="left" rowspan="1" colspan="1">0.01&#x000b1;0.1</td><td valign="top" align="left" rowspan="1" colspan="1">0.34</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">p-value</td><td valign="top" align="left" rowspan="1" colspan="1">0.10</td><td valign="top" align="left" rowspan="1" colspan="1">0.95</td><td valign="top" align="left" rowspan="1" colspan="1"/></tr></tbody></table></table-wrap></floats-group></article>